MetaCap

Dogwood Therapeutics (DWTX) vs Pliant Therapeutics (PLRX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pliant Therapeutics (PLRX) has outperformed Dogwood Therapeutics (DWTX) over the past year, losing 61.6% versus a loss of 83.7%. Over five years, PLRX leads with a -95.9% price change compared with -99.2% for DWTX. Dogwood Therapeutics is the larger company by market cap ($39.6 million vs $36.9 million), about 1.1 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

DWTX-83.68%PLRX-61.61%
+12%-38%-88%
Nov 21, 20251 yearNov 20, 2026
DWTX-99.25%PLRX-96.03%
+144%+17%-111%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

DWTX versus PLRX key metrics
MetricDWTXPLRX
Share price$1.04$0.5951
Market cap$39.57M$36.89M
1-day change-2.36%-4.02%
YTD return-75.12%-51.22%
1-year return-83.68%-61.61%
5-year return-99.16%-95.89%
P/E ratio (TTM)0.10—
EPS (TTM)$10.26$-1.46
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$0
Net income (latest FY)$-34.26M$-149.34M
52-week high$7.04$1.67
52-week low$0.901$0.5719
Distance from 52-week high-85.31%-64.37%
Analyst consensusnonenone
Avg. price target upside+1252.66%+236.08%
Average volume89.88K408.93K
Shares outstanding38.23M61.99M
Employees849
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PLRX has outperformed DWTX by 22.1 percentage points over the past year.

About Dogwood Therapeutics

DWTX stock →

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a combination of valacyclovir and celecoxib intended to synergistically suppress herpesvirus activation; and Serpin Peptide 16 that is in early Phase 1 development to reduce neuropathy secondary to treat chemotherapeutic agents that are neurotoxic.

Health Care · Biotechnology: Pharmaceutical Preparations · 8 employees

About Pliant Therapeutics

PLRX stock →

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors.

Health Care · Biotechnology: Pharmaceutical Preparations · 49 employees

DWTX vs PLRX FAQ

Which is bigger, Dogwood Therapeutics or Pliant Therapeutics?

Dogwood Therapeutics (DWTX) is larger, with a market capitalization of $39.57M compared with $36.89M for Pliant Therapeutics (PLRX).

Which stock has performed better over the past year, DWTX or PLRX?

PLRX returned -61.61% over the past 12 months, compared with -83.68% for DWTX (price return, excluding dividends). Past performance does not predict future results.

Are Dogwood Therapeutics and Pliant Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons